Manufacturers report positive data from post-hoc analysis of 6 years data from phase III open-label extension studies for ocrelizumab in relapsing multiple sclerosis

Analysis found that earlier treatment initiation with ocrelizumab resulted in reduced risk of needing a walking aid by 49% compared to patients who switched from interferon beta-1a two years later.


Biospace Inc.